Merck, Bristol heat up immunotherapy race in lung cancer
January 12, 2015 at 15:34 PM EST
Jan 12 (Reuters) - Bristol-Myers Squibb and Merck & Co broke further away from rival drugmakers in the race to treat lung cancer with a new generation of immune system therapies, adding pressure on the likes of Roche and AstraZeneca to play catch-up.